Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Vaccine Booster

NCT05897190 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

SARS-CoV-2

Interventions

BIOLOGICAL: SARS-CoV-2 mRNA vaccine (RBMRNA-405)
BIOLOGICAL: CoronaVac®

Sponsor

Argorna Pharmaceuticals Co., LTD